tiprankstipranks
Trending News
More News >
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
US Market

Enliven Therapeutics (ELVN) Income Statement

Compare
306 Followers

Enliven Therapeutics Income Statement

Last quarter (Q3 2025), Enliven Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Enliven Therapeutics's net income was $-20.15M. See Enliven Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 104.55M$ 83.53M$ 38.79M$ 24.76M$ 9.32M
Depreciation and Amortization
$ 317.00K$ 297.00K$ 215.00K$ 115.00K$ 45.00K
EBITDA
$ -104.24M$ -83.23M$ -38.58M$ -24.65M$ -9.27M
Operating Income
$ -104.55M$ -83.53M$ -38.79M$ -24.76M$ -9.32M
Other Income/Expenses
$ 15.76M$ 11.95M$ 1.13M$ 22.00K$ -9.65M
Pretax Income
$ -88.79M$ -71.58M$ -37.66M$ -24.74M$ -18.97M
Net Income
$ -89.02M$ -71.58M$ -37.66M$ -24.74M$ -18.97M
Per Share Metrics
Basic EPS
$ -1.89$ -2.01$ -6.03$ -3.17$ -4.31
Diluted EPS
$ -1.89$ -2.01$ -6.03$ -3.17$ -4.31
Weighted Average Shares Outstanding
47.07M 35.55M 6.25M 7.81M 4.39M
Weighted Average Shares Outstanding (Diluted)
47.07M 35.55M 6.25M 7.82M 4.39M
Currency in USD

Enliven Therapeutics Earnings and Revenue History